Show simple item record

2019-01-21Zeitschriftenartikel DOI: 10.25646/5933
In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review
dc.contributor.authorChemaly, Roy F.
dc.contributor.authorHill, Joshua A.
dc.contributor.authorVoigt, Sebastian
dc.contributor.authorPeggs, Karl S.
dc.date.accessioned2019-03-06T09:34:32Z
dc.date.available2019-03-06T09:34:32Z
dc.date.issued2019-01-21none
dc.identifier.other10.1016/j.antiviral.2019.01.008
dc.identifier.urihttp://edoc.rki.de/176904/5968
dc.description.abstractBackground Double-stranded (ds) DNA virus infections often occur concomitantly in immunocompromised patients. We performed a systematic search of published in vitro activity for nine approved and investigational antivirals to understand the spectrum of in vitro activity against dsDNA viruses. Methods A literature search was performed (PubMed and the WoS Core Collection) using keywords related to: 1) targeted approved/developmental antivirals (acyclovir, artesunate, brincidofovir, cidofovir, cyclopropavir (filociclovir), foscarnet, ganciclovir, letermovir, and maribavir); 2) pathogenic dsDNA viruses; 3) in vitro activity. We summarized data from 210 publications. Results Activity against ≤3 viruses was documented for maribavir (cytomegalovirus, Epstein-Barr virus), and letermovir, while activity against > 3 viruses was shown for ganciclovir, cidofovir, acyclovir, foscarnet, cyclopropavir, artesunate, and brincidofovir. The EC50 values of brincidofovir were the lowest, ranging from 0.001 to 0.27 μM, for all viruses except papillomaviruses. The next most potent agents included cidofovir, ganciclovir, foscarnet, and acyclovir with EC50 values between 0.1 μM and >10 μM for cytomegalovirus, herpes simplex virus, and adenovirus. Conclusion Most of the identified antivirals had in vitro activity against more than one dsDNA virus. Brincidofovir and cidofovir have broad-spectrum activity, and brincidofovir has the lowest EC50 values. These findings could assist clinical practice and developmental research.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectIn vitroeng
dc.subjectAntiviraleng
dc.subjectdsDNA viruseng
dc.subjectEC50eng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleIn vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature reviewnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/5968-9
dc.identifier.doihttp://dx.doi.org/10.25646/5933
dc.type.versionpublishedVersionnone
local.edoc.container-titleAntiviral Researchnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S0166354218306570?via%3Dihubnone
local.edoc.container-publisher-nameElseviernone
local.edoc.container-volume2019none
local.edoc.container-issue163none
local.edoc.container-reportyear2019none
local.edoc.container-year2019none
local.edoc.container-firstpage50none
local.edoc.container-lastpage58none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Show simple item record